Gene therapy research and drug development are often hindered by the limited availability of large-scale viral vector manufacturing and the need for comprehensive preclinical evaluation services. Traditional methods can be inefficient, costly, and lack the integrated solutions required for streamlined development.

Genevoyager provides contract research and manufacturing services to accelerate gene therapy development, offering solutions from early discovery to GMP production. Leveraging its proprietary One-Bac 4.0 system, Genevoyager enables high-yield, cost-effective manufacturing of AAV vectors and VLPs. The company's CRO services include target discovery, vector design, preclinical evaluation, and analytical testing, providing a comprehensive suite of tools for advancing gene therapies from bench to clinic. Genevoyager's CDMO capabilities encompass cell line development, process optimization, scale-up, and GMP manufacturing, ensuring a seamless transition from research to commercialization.

One-Bac 4.0 system for high-yield AAV vector production

CDMO services for AAV vectors, proteins, and VLPs

CRO services for drug discovery, preclinical evaluation, and IND-enabling studies

AAV serotype screening and optimization

Custom AAV vector design and manufacturing

Cell line development and GMP cell banking

Analytical testing and quality control

Animal disease model construction and validation

GMP-grade AAV vector production

Genevoyager serves pharmaceutical and biotech companies, academic researchers, and clinical organizations involved in gene therapy research, drug development, and manufacturing.